Presentation is loading. Please wait.

Presentation is loading. Please wait.

Meta-analysis of risk ratios for percentage of patients who developed catheter-associated urinary tract infection, for intervention versus control groups,

Published byĒΜιχαήλ Φιλιππίδης Modified over 5 years ago

Similar presentations

Presentation on theme: "Meta-analysis of risk ratios for percentage of patients who developed catheter-associated urinary tract infection, for intervention versus control groups,"— Presentation transcript:

1 Meta-analysis of risk ratios for percentage of patients who developed catheter-associated urinary tract infection, for intervention versus control groups, stratified by type of intervention to prompt catheter removal. Meta-analysis of risk ratios for percentage of patients who developed catheter-associated urinary tract infection, for intervention versus control groups, stratified by type of intervention to prompt catheter removal. Jennifer Meddings et al. BMJ Qual Saf doi: /bmjqs Copyright © BMJ Publishing Group Ltd and the Health Foundation. All rights reserved.

Download ppt "Meta-analysis of risk ratios for percentage of patients who developed catheter-associated urinary tract infection, for intervention versus control groups,"

Similar presentations

 Categorisation of direct and indirect admissions to the intensive care unit (ICU) from emergency departments (EDs), using source of admission.  Categorisation.

 Categorisation of direct and indirect admissions to the intensive care unit (ICU) from emergency departments (EDs), using source of admission.  Categorisation.
QI Tools: Run Charts.

QI Tools: Run Charts.
Chart 3: Working example of oxygen section for hospital prescription charts (two panels are required on the prescription chart because oxygen may change.

Chart 3: Working example of oxygen section for hospital prescription charts (two panels are required on the prescription chart because oxygen may change.
Lifecycle of the urinary catheter

Lifecycle of the urinary catheter
The 11 dimensions of simulation applications.

The 11 dimensions of simulation applications.
Masashi Maeda et al. Heart Asia 2013;5:7-14

Masashi Maeda et al. Heart Asia 2013;5:7-14
Preprocedure patient ranking of aspects of their care important for obtaining satisfaction with their colonoscopy experience (1=high, 15=low for importance)

Preprocedure patient ranking of aspects of their care important for obtaining satisfaction with their colonoscopy experience (1=high, 15=low for importance)
Effect of confidence interval reduction to demonstrate a true difference in means. Effect of confidence interval reduction to demonstrate a true difference.

Effect of confidence interval reduction to demonstrate a true difference in means. Effect of confidence interval reduction to demonstrate a true difference.
Measure-specific reasons for exclusion (2010-Q4–2013-Q3).

Measure-specific reasons for exclusion (2010-Q4–2013-Q3).
Subgroup analysis of the 17 trials comparing haloperidol and placebo in schizophrenia (outcome: response rate). Subgroup analysis of the 17 trials comparing.

Subgroup analysis of the 17 trials comparing haloperidol and placebo in schizophrenia (outcome: response rate). Subgroup analysis of the 17 trials comparing.
Funnel plot of the 17 trials comparing haloperidol and placebo in schizophrenia (outcome: response rate). Funnel plot of the 17 trials comparing haloperidol.

Funnel plot of the 17 trials comparing haloperidol and placebo in schizophrenia (outcome: response rate). Funnel plot of the 17 trials comparing haloperidol.
Example action effect diagram for a chronic obstructive pulmonary disease improvement initiative constructed retrospectively at the end of the initiative.

Example action effect diagram for a chronic obstructive pulmonary disease improvement initiative constructed retrospectively at the end of the initiative.
A multidimensional framework for patient and family engagement in health and healthcare.33 This figure builds upon Arnstein's34 widely quoted ‘ladder of.

A multidimensional framework for patient and family engagement in health and healthcare.33 This figure builds upon Arnstein's34 widely quoted ‘ladder of.
Percentage change in mean subscale score for nausea/vomiting (A), postprandial fullness/early satiety (B) and bloating (C) for all patients (n=23) and.

Percentage change in mean subscale score for nausea/vomiting (A), postprandial fullness/early satiety (B) and bloating (C) for all patients (n=23) and.
Predicted probability of reporting high speaking up frequency (≥the population median) relative to encouraging environment (EES, increasing values with.

Predicted probability of reporting high speaking up frequency (≥the population median) relative to encouraging environment (EES, increasing values with.
Ratings of core domains stratified by stakeholder group in the second Delphi round. Ratings of core domains stratified by stakeholder group in the second.

Ratings of core domains stratified by stakeholder group in the second Delphi round. Ratings of core domains stratified by stakeholder group in the second.
Example reporting events by odds ratio using hierarchal modelling with shrinkage adjustment. Example reporting events by odds ratio using hierarchal modelling.

Example reporting events by odds ratio using hierarchal modelling with shrinkage adjustment. Example reporting events by odds ratio using hierarchal modelling.
A multidimensional framework for patient and family engagement in health and healthcare.33 This figure builds upon Arnstein's34 widely quoted ‘ladder of.

A multidimensional framework for patient and family engagement in health and healthcare.33 This figure builds upon Arnstein's34 widely quoted ‘ladder of.
Trends in relative risk of death before a mortality alert and after postalert 9-month lag period for (A) all diagnosis/procedure groups (for values 

Trends in relative risk of death before a mortality alert and after postalert 9-month lag period for (A) all diagnosis/procedure groups (for values 
Risk of having any adverse effects with supplements compared with placebo. Risk of having any adverse effects with supplements compared with placebo. Stratified.

Risk of having any adverse effects with supplements compared with placebo. Risk of having any adverse effects with supplements compared with placebo. Stratified.

Similar presentations

Ads by Google